Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Milton S. Hershey Medical Center
Since the regimen of bevacizumab, carboplatin and paclitaxel has become a standard regimen for the treatment of advanced non-squamous NSCLC, new studies in this patient population will have to include this as a reference arm. Addition of a fourth anti-cancer agent has now become the new strategy to improve the outcome for advanced non-squamous NSCLC. Since the regimen of Vorinostat, Carboplatin and Paclitaxel is already in advanced stage of development it is important to study the safety and tolerability of Vorinostat in combination with the three-drug regimen of Bevacizumab, Carboplatin and Paclitaxel. Therefore, we will evaluate Vorinostat when administered in combination with the regimen of Carboplatin, Paclitaxel and Bevacizumab for patients with previously untreated advanced non-small cell lung cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced non-squamous NSCLC
No prior chemotherapy for advanced disease
ECOG performance status 0 or 1
Measurable disease
Life expectancy \> 3 months
Normal bone marrow, renal and hepatic function
Ability to take oral medications
Willingness to sign informed consent
You may not be if
History of brain metastasis
Evidence of thromboembolic phenomenon and treatment with anticoagulants